Catalyst Pharmaceuticals, Inc.

CPRX

$22.60

Name : Catalyst Pharmaceuticals, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $2,777,819,904.00

EPSttm : 1.71

Catalyst Pharmaceuticals, Inc.

$22.60

0.53%

$0.12

Float Short %

7.15

Margin Of Safety %

Put/Call OI Ratio

0.2

EPS Next Q Diff

-0.05

EPS Last/This Y

1.12

EPS This/Next Y

0.08

Price

22.59

Target Price

34.86

Analyst Recom

1.14

Performance Q

10.84

Relative Volume

1.06

Beta

0.73

Ticker: CPRX

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-10	CPRX	22.8	1.12	15.14	9256
2025-12-11	CPRX	22.93	1.17	0.19	9471
2025-12-12	CPRX	23.62	1.16	0.14	9495
2025-12-15	CPRX	24.18	1.14	0.29	9632
2025-12-16	CPRX	24.2	1.11	0.21	9820
2025-12-17	CPRX	24.01	1.13	0.75	9778
2025-12-18	CPRX	23.68	1.16	0.47	9658
2025-12-19	CPRX	23.74	1.17	4.96	9576
2025-12-22	CPRX	24.32	0.23	0.05	1742
2025-12-23	CPRX	24.24	0.17	0.01	2628
2025-12-26	CPRX	24.34	0.09	0.34	4835
2025-12-29	CPRX	24.05	0.09	0.14	4928
2025-12-30	CPRX	23.28	0.10	0.23	5459
2025-12-31	CPRX	23.32	0.11	0.06	5842
2026-01-02	CPRX	23.16	0.11	4.87	6186
2026-01-05	CPRX	22.81	0.19	0.65	6666
2026-01-06	CPRX	22.58	0.19	0.32	6686
2026-01-07	CPRX	22.73	0.19	0.52	6725
2026-01-08	CPRX	22.59	0.20	0.41	6825
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-10	CPRX	22.55	-33.8	43.0	2.50
2025-12-11	CPRX	22.94	-33.8	40.8	2.50
2025-12-12	CPRX	23.61	-33.8	50.2	2.50
2025-12-15	CPRX	24.18	-33.8	48.0	2.50
2025-12-16	CPRX	24.18	-33.8	38.5	2.50
2025-12-17	CPRX	24.00	-33.8	35.5	2.50
2025-12-18	CPRX	23.67	-33.8	33.3	2.50
2025-12-19	CPRX	23.75	-33.8	40.0	2.50
2025-12-22	CPRX	24.28	-33.8	47.5	2.50
2025-12-23	CPRX	24.19	-33.8	36.7	2.50
2025-12-26	CPRX	24.35	-33.8	37.1	2.50
2025-12-29	CPRX	24.05	-33.8	33.9	2.50
2025-12-30	CPRX	23.28	-33.8	26.2	2.50
2025-12-31	CPRX	23.32	-33.8	39.2	2.50
2026-01-02	CPRX	23.15	-33.8	35.4	2.50
2026-01-05	CPRX	22.81	-33.8	32.8	2.50
2026-01-06	CPRX	22.58	-33.8	34.9	2.50
2026-01-07	CPRX	22.73	-33.8	41.3	2.50
2026-01-08	CPRX	22.59	-15.0	36.5	2.50
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-10	CPRX	-3.66	1.60	7.16
2025-12-11	CPRX	-2.10	1.60	7.16
2025-12-12	CPRX	-2.10	1.60	7.16
2025-12-15	CPRX	-2.06	1.77	7.16
2025-12-16	CPRX	-2.29	1.77	7.19
2025-12-17	CPRX	-2.21	1.77	7.19
2025-12-18	CPRX	-2.21	1.77	7.19
2025-12-19	CPRX	-2.21	1.77	7.19
2025-12-22	CPRX	-2.21	1.72	7.19
2025-12-23	CPRX	-2.21	1.72	7.19
2025-12-26	CPRX	-2.21	1.72	7.15
2025-12-29	CPRX	-2.21	1.71	7.15
2025-12-30	CPRX	-2.21	1.71	7.15
2025-12-31	CPRX	-2.21	1.71	7.15
2026-01-02	CPRX	-2.21	1.71	7.15
2026-01-05	CPRX	-2.21	1.57	7.15
2026-01-06	CPRX	-2.20	1.57	7.15
2026-01-07	CPRX	-2.20	1.57	7.15
2026-01-08	CPRX	-2.20	1.57	7.15
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

0.64

Avg. EPS Est. Current Quarter

0.46

Avg. EPS Est. Next Quarter

0.59

Insider Transactions

-2.2

Institutional Transactions

1.57

Beta

0.73

Average Sales Estimate Current Quarter

141

Average Sales Estimate Next Quarter

142

Fair Value

28.72

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-45.4

Target Price

34.86

P/E

13.19

Forward P/E

12.9

PEG

1.06

P/S

4.8

P/B

3.03

P/Free Cash Flow

11.84

EPS

1.71

Average EPS Est. Cur. Y

2.5

EPS Next Y. (Est.)

2.58

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

37.63

Relative Volume

1.06

Return on Equity vs Sector %

-3.7

Return on Equity vs Industry %

11.7

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.16

EBIT Estimation

36.5

Catalyst Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 181

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

stock quote shares CPRX – Catalyst Pharmaceuticals, Inc. Stock Price stock today

news today CPRX – Catalyst Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch CPRX – Catalyst Pharmaceuticals, Inc. yahoo finance google finance

stock history CPRX – Catalyst Pharmaceuticals, Inc. invest stock market

stock prices CPRX premarket after hours

ticker CPRX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: CPRX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y